ArticleFrontiers in molecular biosciences2025

Rapamycin combined with osimertinib alleviated non-small cell lung cancer by regulating the PARP, Akt/mTOR, and MAPK/ERK signaling pathways.

Qingrong Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.